JPWO2022270487A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022270487A5
JPWO2022270487A5 JP2023530474A JP2023530474A JPWO2022270487A5 JP WO2022270487 A5 JPWO2022270487 A5 JP WO2022270487A5 JP 2023530474 A JP2023530474 A JP 2023530474A JP 2023530474 A JP2023530474 A JP 2023530474A JP WO2022270487 A5 JPWO2022270487 A5 JP WO2022270487A5
Authority
JP
Japan
Prior art keywords
compound
pharma
acceptable salt
alkyl
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023530474A
Other languages
English (en)
Japanese (ja)
Other versions
JP7531947B2 (ja
JPWO2022270487A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/024638 external-priority patent/WO2022270487A1/ja
Publication of JPWO2022270487A1 publication Critical patent/JPWO2022270487A1/ja
Publication of JPWO2022270487A5 publication Critical patent/JPWO2022270487A5/ja
Application granted granted Critical
Publication of JP7531947B2 publication Critical patent/JP7531947B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023530474A 2021-06-22 2022-06-21 化合物、エンドセリンａ受容体拮抗剤及び医薬組成物 Active JP7531947B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021103047 2021-06-22
JP2021103047 2021-06-22
PCT/JP2022/024638 WO2022270487A1 (ja) 2021-06-22 2022-06-21 化合物、エンドセリンａ受容体拮抗剤及び医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2022270487A1 JPWO2022270487A1 (https=) 2022-12-29
JPWO2022270487A5 true JPWO2022270487A5 (https=) 2024-07-11
JP7531947B2 JP7531947B2 (ja) 2024-08-13

Family

ID=84545734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530474A Active JP7531947B2 (ja) 2021-06-22 2022-06-21 化合物、エンドセリンａ受容体拮抗剤及び医薬組成物

Country Status (12)

Country Link
US (1) US20240287053A1 (https=)
EP (1) EP4361146A4 (https=)
JP (1) JP7531947B2 (https=)
KR (1) KR20240022646A (https=)
CN (1) CN117255791A (https=)
AR (1) AR126178A1 (https=)
AU (1) AU2022297082B2 (https=)
BR (1) BR112023019460A2 (https=)
CA (1) CA3217189A1 (https=)
IL (1) IL306095A (https=)
MX (1) MX2023014455A (https=)
WO (1) WO2022270487A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514696A (en) 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
ATE243203T1 (de) 1995-04-04 2003-07-15 Texas Biotechnology Corp Thienyl-, furyl-, pyrrolyl- und biphenylsulfonamide und derivate zur modulation der endothelin-aktivität
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
WO1998033781A1 (en) 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
JP3455233B2 (ja) 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
MXPA02006461A (es) * 1999-12-31 2003-09-05 Texas Biotechnology Corp Sulfonamidas y derivados de las mismas que modulan la actividad de endotelina.
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US8592470B2 (en) * 2012-01-31 2013-11-26 Eisai R&D Management Co., Ltd. Sitaxentan derivative
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines

Similar Documents

Publication Publication Date Title
JP2007524696A5 (https=)
JP2019094345A5 (https=)
JP2006507355A5 (https=)
JP2021516240A5 (https=)
JP2020169171A5 (https=)
JP2023533203A5 (https=)
WO2008064116A2 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2014503574A5 (https=)
EA009743B1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
JP2006524222A5 (https=)
JP2007530696A5 (https=)
JP2023531709A5 (https=)
JP2025505644A5 (https=)
JP2020507566A5 (https=)
JP2019507114A5 (https=)
JP2002529465A5 (https=)
RU2007108863A (ru) Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3
US20160175316A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2022533939A5 (https=)
JP2017519796A5 (https=)
JP2023531495A5 (https=)
JP2004507527A5 (https=)
JP2017532294A5 (https=)
JPWO2022270487A5 (https=)
JP2007538031A5 (https=)